22Dec
Cadent Therapeutics Acquired by Novartis for Up to $770 Million
Cadent Therapeutics, a Cambridge, Massachusetts-based, privately held clinical stage biopharmaceutical company focused on the development of therapies for the treatment of cognitive, mood, and movement disorders, announced on December 17, 2020, that Novartis will acquire all of the outstanding capital stock of Cadent Therapeutics....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
The Bechtel National appeal provided the Federal Circuit with an opportunity to provide clarity to b...
Read More >
As the pandemic continues to change the economic landscape, financial services companies and investo...
Read More >
California Governor Gavin Newsom wasted little time by signing AB 5 into law yesterday, and his sign...
Read More >
On January 28, 2020, the Federal Trade Commission (FTC) announced its annual increase of the jurisdi...
Read More >
On August 9, 2019, the National Labor Relations Board (Board) published a Notice of Proposed Rulemak...
Read More >
In connection with the purchase and sale of the stock of a target corporation (a Corporate Target), ...
Read More >